Mark Wiggins

Mark Wiggins is Senior Vice President, Business and Corporate Development at Elcelyx Therapeutics, where he leads  strategic financing and partnering activities.  Mr. Wiggins was formerly Chief Business Officer of Mpex Pharmaceuticals where he led commercial planning activities for an inhaled antibiotic for cystic fibrosis as well as business development activities, resulting in the successful acquisition by Axcan (now Aptalis).  Prior to Mpex he was Executive Vice President of Business and Corporate Development and was a member of the Executive Committee at Biogen Idec.  Mr. Wiggins was also head of marketing and played a key role in the collaboration and product launch with Genentech of Rituxan®, a $6 billion product for cancer and autoimmune disorders. As global head of business development, Mr. Wiggins and his team acquired three companies and completed over 15 significant licensing/partnering transactions, many of which are significant value drivers for Biogen Idec today. Prior to Biogen Idec, Mr. Wiggins worked in marketing and business development with Schering-Plough (now Merck), Johnson & Johnson and Pfizer Pharmaceuticals. Mr. Wiggins received his BS degree in finance from Syracuse University and an MBA from the University of Arizona Eller College of Management.